Compare SNDX & JJSF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNDX | JJSF |
|---|---|---|
| Founded | 2005 | 1971 |
| Country | United States | United States |
| Employees | N/A | 1800 |
| Industry | Biotechnology: Pharmaceutical Preparations | Specialty Foods |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.6B |
| IPO Year | 2014 | 1995 |
| Metric | SNDX | JJSF |
|---|---|---|
| Price | $24.21 | $76.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 2 |
| Target Price | $84.17 | ★ $140.00 |
| AVG Volume (30 Days) | ★ 1.3M | 208.2K |
| Earning Date | 05-04-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 4.29% |
| EPS Growth | ★ 11.56 | N/A |
| EPS | N/A | ★ 0.05 |
| Revenue | $172,352,000.00 | ★ $1,022,038,000.00 |
| Revenue This Year | $112.05 | $0.43 |
| Revenue Next Year | $51.24 | $1.70 |
| P/E Ratio | ★ N/A | $1,493.40 |
| Revenue Growth | ★ 627.84 | N/A |
| 52 Week Low | $8.59 | $73.76 |
| 52 Week High | $25.44 | $142.69 |
| Indicator | SNDX | JJSF |
|---|---|---|
| Relative Strength Index (RSI) | 65.43 | 32.98 |
| Support Level | $19.46 | N/A |
| Resistance Level | $25.16 | $87.73 |
| Average True Range (ATR) | 1.09 | 2.39 |
| MACD | 0.08 | -0.78 |
| Stochastic Oscillator | 72.18 | 21.33 |
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
J&J Snack Foods Corp. manufactures snack foods and distributes frozen beverages, which it markets nationally to the foodservice and retail supermarket industries. The company's portfolio of frozen beverages, frozen novelties, and baked goods includes soft pretzels, frozen juice treats and desserts, stuffed sandwiches, churros, funnel cakes, cookies, and other snack foods and drinks. It operates through three segments: Food Service, which sells snacks, desserts, and baked goods at the point of sale; Retail Supermarkets, which sells frozen and prepackaged products to supermarkets; and Frozen Beverages, which sells frozen beverages under the ICEE, Slush Puppie, and Parrot Ice brands in the United States, Mexico, and Canada. The majority of revenue comes from the Food Service segment.